^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoSweep™

    Company:
    Pharus Diagnostics
    Type:
    Laboratory Developed Test
    Details
    Evidence

    News

    9ms
    Pharus Diagnostics signs worldwide exclusive license agreement with City of Hope for novel biomarkers to be used in liquid biopsy screening for early pancreatic cancer diagnosis (BioSpace)
    "Pharus Diagnostics...announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license agreement marks a pivotal step with PharusDx to develop and commercialize a version of its OncoSweep™ liquid biopsy screening for the early detection of PDAC. OncoSweep™ aims to improve on the current standard for early diagnosis of PDAC, offering a non-invasive solution that has been shown in laboratory studies to be highly accurate."
    Licensing / partnership
    |
    OncoSweep™
    9ms
    CPIP-LUN-A001: OncoSweep Cancer Spotlight and Spectrum Product Line (clinicaltrials.gov)
    P=N/A; N=800; Recruiting; Sponsor:Pharus Taiwan, Inc.
    New trial
    |
    OncoSweep™